Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)
Guggenheim analyst Yatin Suneja reiterated a Buy rating for Cabaletta Bio with a $15.00 price target. The stock closed at $2.45, indicating significant upside potential. Suneja, a 5-star analyst, has a 21.2% average return and a 55.18% success rate. The consensus among analysts is a Strong Buy with a $17.83 average price target, suggesting a 627.76% upside. H.C. Wainwright also reiterated a Buy rating with a $16.00 price target.
Guggenheim analyst Yatin Suneja reiterated a Buy rating on Cabaletta Bio on November 12 and set a price target of $15.00. The company’s shares closed yesterday at $2.45.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Suneja is a 5-star analyst with an average return of 21.2% and a 55.18% success rate. Suneja covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, Adicet Bio, and Praxis Precision Medicines.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $17.83 average price target, representing a 627.76% upside. In a report released on November 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.
